1096 related articles for article (PubMed ID: 28535653)
1. [Clinical pathological characteristics of resectable papillary thyroid microcarcinoma].
Shi CL; Guo Y; Lyu YC; Nanding ZABYS; Gao WC; Shi TF; Qin HD; Liu SY
Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):361-366. PubMed ID: 28535653
[No Abstract] [Full Text] [Related]
2. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.
Shi C; Guo Y; Lv Y; Nanding A; Shi T; Qin H; He J
PLoS One; 2016; 11(12):e0167414. PubMed ID: 27936049
[TBL] [Abstract][Full Text] [Related]
3. [Invasiveness of papillary thyroid microcarcinoma with BRAF mutation].
Yang X; Liang ZY; Meng C; Liang J; Yu Z; Lin YS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Aug; 35(4):398-403. PubMed ID: 23987486
[TBL] [Abstract][Full Text] [Related]
4. The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors.
Choi SY; Park H; Kang MK; Lee DK; Lee KD; Lee HS; Kim SW; Lee EN; Hong JC
World J Surg Oncol; 2013 Nov; 11():291. PubMed ID: 24228637
[TBL] [Abstract][Full Text] [Related]
5. Papillary microcarcinoma of the thyroid: clinical characteristics and BRAF(V600E) mutational status of 977 cases.
Zheng X; Wei S; Han Y; Li Y; Yu Y; Yun X; Ren X; Gao M
Ann Surg Oncol; 2013 Jul; 20(7):2266-73. PubMed ID: 23370668
[TBL] [Abstract][Full Text] [Related]
6. BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness.
Kurtulmus N; Duren M; Ince U; Cengiz Yakicier M; Peker O; Aydın O; Altiok E; Giray S; Azizlerli H
Endocrine; 2012 Oct; 42(2):404-10. PubMed ID: 22426956
[TBL] [Abstract][Full Text] [Related]
7. Potential relationship between Hashimoto's thyroiditis and BRAF(V600E) mutation status in papillary thyroid cancer.
Zeng RC; Jin LP; Chen ED; Dong SY; Cai YF; Huang GL; Li Q; Jin C; Zhang XH; Wang OC
Head Neck; 2016 Apr; 38 Suppl 1():E1019-25. PubMed ID: 26041461
[TBL] [Abstract][Full Text] [Related]
8. Risk factors contributing to the difference in prognosis for papillary versus micropapillary thyroid carcinoma.
Karatzas T; Vasileiadis I; Kapetanakis S; Karakostas E; Chrousos G; Kouraklis G
Am J Surg; 2013 Oct; 206(4):586-93. PubMed ID: 23790258
[TBL] [Abstract][Full Text] [Related]
9. Predicting factors of central lymph node metastasis and BRAF
Zhou SL; Guo YP; Zhang L; Deng T; Xu ZG; Ding C; Sun WC; Zhao YW; Kong LF
World J Surg Oncol; 2021 Jul; 19(1):211. PubMed ID: 34256769
[TBL] [Abstract][Full Text] [Related]
10. Associations of the BRAF(V600E) mutation with sonographic features and clinicopathologic characteristics in a large population with conventional papillary thyroid carcinoma.
Park AY; Son EJ; Kim JA; Youk JH; Park YJ; Park CS; Chang HS
PLoS One; 2014; 9(10):e110868. PubMed ID: 25337709
[TBL] [Abstract][Full Text] [Related]
11. BRAF
Zhao H; Liu CH; Lu Y; Liu SZ; Yeerkenbieke P; Cao Y; Xia Y; Gao LY; Liu YW; Liu ZW; Chen SG; Liang ZY; Li XY
Oral Oncol; 2024 May; 152():106755. PubMed ID: 38547780
[TBL] [Abstract][Full Text] [Related]
12. Combined effect of Hashimoto's thyroiditis and BRAF(V600E) mutation status on aggressiveness in papillary thyroid cancer.
Kim SJ; Myong JP; Jee HG; Chai YJ; Choi JY; Min HS; Lee KE; Youn YK
Head Neck; 2016 Jan; 38(1):95-101. PubMed ID: 25213729
[TBL] [Abstract][Full Text] [Related]
13. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.
Kim TY; Kim WB; Rhee YS; Song JY; Kim JM; Gong G; Lee S; Kim SY; Kim SC; Hong SJ; Shong YK
Clin Endocrinol (Oxf); 2006 Sep; 65(3):364-8. PubMed ID: 16918957
[TBL] [Abstract][Full Text] [Related]
14. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
[TBL] [Abstract][Full Text] [Related]
15. Does papillary thyroid carcinoma have a better prognosis with or without Hashimoto thyroiditis?
Kwak HY; Chae BJ; Eom YH; Hong YR; Seo JB; Lee SH; Song BJ; Jung SS; Bae JS
Int J Clin Oncol; 2015 Jun; 20(3):463-73. PubMed ID: 25312294
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.
Choi EK; Chong A; Ha JM; Jung CK; O JH; Kim SH
Clin Endocrinol (Oxf); 2017 Jul; 87(1):73-79. PubMed ID: 28329426
[TBL] [Abstract][Full Text] [Related]
17. Significance of multifocality in papillary thyroid carcinoma.
Feng JW; Qu Z; Qin AC; Pan H; Ye J; Jiang Y
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1820-1828. PubMed ID: 32732090
[TBL] [Abstract][Full Text] [Related]
18. [Correlation between Ultrasound-guided Fine-needle Aspiration Combined with BRAF
Zhang Y; Luo YK; Zhang Y; Zhang MB; Guang Y; Xie F; Jiang B; Tang J
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2019 Aug; 41(4):517-523. PubMed ID: 31484615
[TBL] [Abstract][Full Text] [Related]
19. BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma.
Gu LQ; Li FY; Zhao L; Liu Y; Zang XX; Wang TX; Chen HP; Ning G; Zhao YJ
Thyroid; 2009 Apr; 19(4):347-54. PubMed ID: 19355825
[TBL] [Abstract][Full Text] [Related]
20. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
